Cancer NetworkOriginal article
<![CDATA[Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression]]>
Data Readoutpositiverinatabart sesutecanPositive
AI Analysis
Summary
Data from the RAINFOL-01 trial demonstrated that rinatabart sesutecan elicited clinical responses in heavily pretreated platinum-resistant ovarian cancer patients regardless of FRα expression status, suggesting broader applicability than FRα-dependent mechanisms.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression in RAINFOL-01 trial
Importance:6/10
Sentiment:
0.70
oncologyovarian cancerFRα expressionplatinum-resistantRAINFOL-01
Read the original article
Published by Cancer Network on October 5, 2026 6:31 PM